PUBLISHED NEWS OUR RSS NEWS CHANNELS SPONSORED ADS Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results Tuesday, 19 February 2008 Onyx Pharmaceuticals, Inc.Today reported its financial results for the three and twelve months ended December 31, 2007.Reported a net loss of $11.Or $0.Share, for the fourth quarter of 2007pared to a net loss of $20.Or $0.Share, in the same period in the prior year.The twelve months ended December 31, 2007, Onyx recorded a net loss of $34.$0.Share,pared with a net loss of $92.Or $2.Share, for the same period in 2006.Nexavar net sales were $124.For the quarter ended December 31, 2007, which represents a 96% increase over the $63.In the same period in 2006 and a 19% increase over the $104.Reported in the quarter ended September 30, 2007.Sales were $371.In 2007, a 125% increase over the $165.Reported in 2006.With its collaborator, Bayer HealthCare Pharmaceuticals Inc.Bayer, is marketing and developing Nexavar(R) (sorafenib) tablets, an anticancer therapy currently approved for the treatment of advanced kidney cancer and liver cancer in the U.European Union, and other territories internationally.Accordance with Onyx's collaboration agreement with Bayer, Bayer recognizes all revenue from the sale of Nexavar."We are pleased with Nexavar's continuedmercial growth, generating worldwide net sales of $124.For the fourth quarter and $371.For 2007," said Hollings C.President, chief executive officer, and chairman of Onyx.Approvals of Nexavar in liver cancer and advanced kidney cancer reinforce ourmitment to invest in Nexavar, bothmercially and clinically, to maximize the full value of this proven anticancer agent.The net loss for the quarter ended December 31, 2007, included employee stock-basedpensation expense of $3.Or $0.Share.Net loss for the quarter ended December 31, 2006, included employee stock-basedpensation expense of $3.Or $0.Share.ABOUT ONYX PHARMACEUTICALS, INC.Inc.A biopharmaceuticalpanymitted to improving the lives of people with cancer by changing the way cancer is treated(TM).In collaboration with Bayer HealthCare Pharmaceuticals, Inc.Developing and marketing Nexavar(R) (sorafenib) tablets, a small molecule drug.Is currently approved for the treatment of advanced kidney cancer and for the treatment of liver cancer.Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer and other tumor types.Read more Periogard(chlorhexidine gluconate) liquid [colgate oral pharmaceuticals inc.]
Get more Doubt cast on commonly used severe sepsis treatments
